Skip to main content
Top
Published in: Diabetologia 3/2003

01-03-2003 | Article

Temporal changes in the frequencies of HLA genotypes in patients with Type 1 diabetes—indication of an increased environmental pressure?

Authors: R. Hermann, MD PhD, M. Knip, R. Veijola, O. Simell, A.-P. Laine, H. K. Åkerblom, P.-H. Groop, C. Forsblom, K. Pettersson-Fernholm, J. Ilonen, the FinnDiane Study Group

Published in: Diabetologia | Issue 3/2003

Login to get access

Abstract

Aims/hypothesis

The incidence of Type 1 diabetes has increased 2.5 times during the time period from 1966 to 2000 in Finland—a general trend seen in almost all developed countries that can only be explained by environmental factors. The aim of this study was to test the possible effect of a changing environment on distribution of genotypes associated with disease susceptibility.

Methods

HLA DRB1-DQA1-DQB1 genes and two diabetes-associated polymorphisms at IDDM2 and IDDM12 were analyzed. The frequencies of genotypes were compared between cases diagnosed with childhood-onset Type 1 diabetes during the period of 1939–1965 (n=367) and those diagnosed between 1990 and 2001 (n=736). Chi-square statistics or the Fisher's Exact test were used for the comparison of frequencies of analyzed haplotypes and genotypes in the two groups.

Results

The frequencies of (DR3)-DQA1*05-DQB1*02 and (DR4)-DQB1*0302 risk haplotypes and the high risk (DR3)-DQA1*05-DQB1*02/DRB1*0401-DQB1*0302 genotype were higher while proportion of patients carrying protective haplotypes—(DR15)-DQB1*0602 and (DR1301)-DQB1*0603—or protective genotypes was lower in patients diagnosed before 1965 as compared to those who developed disease after 1990. No temporal variation was found in the frequencies of genotypes at IDDM2 and IDDM12.

Conclusion/interpretation

Our data suggest that the need for genetic susceptibility to develop Type 1 diabetes has decreased over time due to an increasing environmental pressure and this results in a higher disease progression rate especially in subjects with protective HLA genotypes.
Literature
1.
go back to reference Piazza A, Menozzi P, Cavalli-Sforza LL (1980) The HLA-A,B gene frequencies in the world: migration or selection? Hum Immunol 1:297–304CrossRefPubMed Piazza A, Menozzi P, Cavalli-Sforza LL (1980) The HLA-A,B gene frequencies in the world: migration or selection? Hum Immunol 1:297–304CrossRefPubMed
2.
go back to reference Hill AV, Allsopp CE, Kwiatkowski D et al. (1991) Common west African HLA antigens are associated with protection from severe malaria. Nature 352:595–600PubMed Hill AV, Allsopp CE, Kwiatkowski D et al. (1991) Common west African HLA antigens are associated with protection from severe malaria. Nature 352:595–600PubMed
3.
go back to reference Dunstan SJ, Stephens HA, Blackwell JM et al. (2001) Genes of the class II and class III major histocompatibility complex are associated with typhoid fever in Vietnam. J Infect Dis 183:261–268CrossRefPubMed Dunstan SJ, Stephens HA, Blackwell JM et al. (2001) Genes of the class II and class III major histocompatibility complex are associated with typhoid fever in Vietnam. J Infect Dis 183:261–268CrossRefPubMed
4.
go back to reference Thursz MR, Thomas HC, Greenwood BM, Hill AV (1997) Heterozygote advantage for HLA class-II type in hepatitis B virus infection. Nat Genet 17:11–12PubMed Thursz MR, Thomas HC, Greenwood BM, Hill AV (1997) Heterozygote advantage for HLA class-II type in hepatitis B virus infection. Nat Genet 17:11–12PubMed
5.
go back to reference Karvonen M, Viik-Kajander M, Moltchanova E, Libman I, LaPorte R, Tuomilehto J (2000) Incidence of childhood type 1 diabetes worldwide. Diabetes Mondiale (DiaMond) Project Group. Diabetes Care 23:1516–1526PubMed Karvonen M, Viik-Kajander M, Moltchanova E, Libman I, LaPorte R, Tuomilehto J (2000) Incidence of childhood type 1 diabetes worldwide. Diabetes Mondiale (DiaMond) Project Group. Diabetes Care 23:1516–1526PubMed
6.
go back to reference Tuomilehto J, Rewers M, Reunanen A et al. (1991) Increasing trend in Type I (insulin-dependent) diabetes mellitus in childhood in Finland. Analysis of age, calendar time and birth cohort effects during 1965 to 1984. Diabetologia 34:282–287PubMed Tuomilehto J, Rewers M, Reunanen A et al. (1991) Increasing trend in Type I (insulin-dependent) diabetes mellitus in childhood in Finland. Analysis of age, calendar time and birth cohort effects during 1965 to 1984. Diabetologia 34:282–287PubMed
7.
go back to reference Mäenpää A, Koskimies S, Scheinin T et al. (1991) Frequencies of HLA-DR3, -DR4, -B8 and -Bw62 in diabetic children diagnosed between 1960 and 1990. Diabetes Res 16:159–163PubMed Mäenpää A, Koskimies S, Scheinin T et al. (1991) Frequencies of HLA-DR3, -DR4, -B8 and -Bw62 in diabetic children diagnosed between 1960 and 1990. Diabetes Res 16:159–163PubMed
8.
go back to reference Kontiainen S, Scheinin T, Schlenzka A, Mäenpää J, Groop L, Koskimies S (1988) Differences in HLA types in children with insulin-dependent diabetes diagnosed in 1960s, 1970s, and 1980s. Lancet ii:219 Kontiainen S, Scheinin T, Schlenzka A, Mäenpää J, Groop L, Koskimies S (1988) Differences in HLA types in children with insulin-dependent diabetes diagnosed in 1960s, 1970s, and 1980s. Lancet ii:219
9.
go back to reference Nejentsev S, Sjöroos M, Soukka T et al. (1999) Population-based genetic screening for the estimation of Type 1 diabetes mellitus risk in Finland: selective genotyping of markers in the HLA-DQB1, HLA-DQA1 and HLA-DRB1 loci. Diabet Med 16:985–992PubMed Nejentsev S, Sjöroos M, Soukka T et al. (1999) Population-based genetic screening for the estimation of Type 1 diabetes mellitus risk in Finland: selective genotyping of markers in the HLA-DQB1, HLA-DQA1 and HLA-DRB1 loci. Diabet Med 16:985–992PubMed
10.
go back to reference Laaksonen M, Pastinen T, Sjöroos M et al. (2002) HLA class II associated risk and protection against multiple sclerosis—a Finnish family study. J Neuroimmunol 122:140–145CrossRefPubMed Laaksonen M, Pastinen T, Sjöroos M et al. (2002) HLA class II associated risk and protection against multiple sclerosis—a Finnish family study. J Neuroimmunol 122:140–145CrossRefPubMed
11.
go back to reference Chowdhury TA, Dyer PH, Mijovic CH, Dunger DB, Barnett AH, Bain SC (1999) Human leucocyte antigen and insulin gene regions and nephropathy in type I diabetes. Diabetologia 42:1017–1020CrossRefPubMed Chowdhury TA, Dyer PH, Mijovic CH, Dunger DB, Barnett AH, Bain SC (1999) Human leucocyte antigen and insulin gene regions and nephropathy in type I diabetes. Diabetologia 42:1017–1020CrossRefPubMed
12.
go back to reference Ronningen KS, Bangstad HJ, Undlien DE, Thorsby E (1993) Influence of genetic factors (HLA class II genes, insulin-gene region polymorphisms) and metabolic control on the development of diabetic nephropathy. Diabetes Res 23:31–40PubMed Ronningen KS, Bangstad HJ, Undlien DE, Thorsby E (1993) Influence of genetic factors (HLA class II genes, insulin-gene region polymorphisms) and metabolic control on the development of diabetic nephropathy. Diabetes Res 23:31–40PubMed
13.
go back to reference Caillat-Zucman S, Garchon HJ, Timsit J et al. (1992) Age-dependent HLA genetic heterogeneity of type 1 insulin-dependent diabetes mellitus. J Clin Invest 90:2242–2250PubMed Caillat-Zucman S, Garchon HJ, Timsit J et al. (1992) Age-dependent HLA genetic heterogeneity of type 1 insulin-dependent diabetes mellitus. J Clin Invest 90:2242–2250PubMed
14.
go back to reference Komulainen J, Kulmala P, Savola K et al. (1999) Clinical, autoimmune, and genetic characteristics of very young children with type 1 diabetes. Childhood Diabetes in Finland (DiMe) Study Group. Diabetes Care 22:1950–1955PubMed Komulainen J, Kulmala P, Savola K et al. (1999) Clinical, autoimmune, and genetic characteristics of very young children with type 1 diabetes. Childhood Diabetes in Finland (DiMe) Study Group. Diabetes Care 22:1950–1955PubMed
15.
go back to reference Hermann R, Mijovic CH, Rayner M et al. (2001) HLA alleles and IDDM in children in Hungary: a comparison with Finland. Hum Immunol 62:391–398CrossRefPubMed Hermann R, Mijovic CH, Rayner M et al. (2001) HLA alleles and IDDM in children in Hungary: a comparison with Finland. Hum Immunol 62:391–398CrossRefPubMed
16.
go back to reference Nejentsev S, Koskinen S, Sjöroos M et al. (1998) Distribution of insulin-dependent diabetes mellitus (IDDM)-related HLA alleles correlates with the difference in IDDM incidence in four populations of the Eastern Baltic region. Tissue Antigens 52:473–477PubMed Nejentsev S, Koskinen S, Sjöroos M et al. (1998) Distribution of insulin-dependent diabetes mellitus (IDDM)-related HLA alleles correlates with the difference in IDDM incidence in four populations of the Eastern Baltic region. Tissue Antigens 52:473–477PubMed
17.
go back to reference Noble JA, Valdes AM, Cook M, Klitz W, Thomson G, Erlich HA (1996) The role of HLA class II genes in insulin-dependent diabetes mellitus: molecular analysis of 180 Caucasian, multiplex families. Am J Hum Genet 59:1134–1148PubMed Noble JA, Valdes AM, Cook M, Klitz W, Thomson G, Erlich HA (1996) The role of HLA class II genes in insulin-dependent diabetes mellitus: molecular analysis of 180 Caucasian, multiplex families. Am J Hum Genet 59:1134–1148PubMed
18.
go back to reference Viskari HR, Koskela P, Lönnrot M et al. (2000) Can enterovirus infections explain the increasing incidence of type 1 diabetes? Diabetes Care 23:414–416PubMed Viskari HR, Koskela P, Lönnrot M et al. (2000) Can enterovirus infections explain the increasing incidence of type 1 diabetes? Diabetes Care 23:414–416PubMed
19.
go back to reference Bach JF (2002) The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 347:911–920CrossRefPubMed Bach JF (2002) The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 347:911–920CrossRefPubMed
20.
go back to reference Vaarala O (2002) The gut immune system and type 1 diabetes. Ann NY Acad Sci 958:39–46PubMed Vaarala O (2002) The gut immune system and type 1 diabetes. Ann NY Acad Sci 958:39–46PubMed
21.
go back to reference Lucassen AM, Julier C, Beressi JP et al. (1993) Susceptibility to insulin dependent diabetes mellitus maps to a 4.1 kb segment of DNA spanning the insulin gene and associated VNTR. Nat Genet 4:305–310PubMed Lucassen AM, Julier C, Beressi JP et al. (1993) Susceptibility to insulin dependent diabetes mellitus maps to a 4.1 kb segment of DNA spanning the insulin gene and associated VNTR. Nat Genet 4:305–310PubMed
22.
go back to reference Bell GI, Horita S, Karam JH (1984) A polymorphic locus near the human insulin gene is associated with insulin-dependent diabetes mellitus. Diabetes 33:176–183PubMed Bell GI, Horita S, Karam JH (1984) A polymorphic locus near the human insulin gene is associated with insulin-dependent diabetes mellitus. Diabetes 33:176–183PubMed
23.
go back to reference Nistico L, Buzzetti R, Pritchard LE et al. (1996) The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with, type 1 diabetes. Belgian Diabetes Registry. Hum Mol Genet 5:1075–1080PubMed Nistico L, Buzzetti R, Pritchard LE et al. (1996) The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with, type 1 diabetes. Belgian Diabetes Registry. Hum Mol Genet 5:1075–1080PubMed
24.
go back to reference Morahan G, Huang D, Tait BD, Colman PG, Harrison LC (1996) Markers on distal chromosome 2q linked to insulin-dependent diabetes mellitus. Science 272:1808–1810 Morahan G, Huang D, Tait BD, Colman PG, Harrison LC (1996) Markers on distal chromosome 2q linked to insulin-dependent diabetes mellitus. Science 272:1808–1810
25.
go back to reference Marron MP, Raffel LJ, Garchon HJ et al. (1997) Insulin-dependent diabetes mellitus (IDDM) is associated with CTLA4 polymorphisms in multiple ethnic groups. Hum Mol Genet 6:1275–1282CrossRefPubMed Marron MP, Raffel LJ, Garchon HJ et al. (1997) Insulin-dependent diabetes mellitus (IDDM) is associated with CTLA4 polymorphisms in multiple ethnic groups. Hum Mol Genet 6:1275–1282CrossRefPubMed
Metadata
Title
Temporal changes in the frequencies of HLA genotypes in patients with Type 1 diabetes—indication of an increased environmental pressure?
Authors
R. Hermann, MD PhD
M. Knip
R. Veijola
O. Simell
A.-P. Laine
H. K. Åkerblom
P.-H. Groop
C. Forsblom
K. Pettersson-Fernholm
J. Ilonen
the FinnDiane Study Group
Publication date
01-03-2003
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 3/2003
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-003-1045-4

Other articles of this Issue 3/2003

Diabetologia 3/2003 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.